Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 6/20 | 0.53 |
| ▸ | PPARD | Q03181 | 6/20 | 0.53 |
| ▸ | PPARA | Q07869 | 5/20 | 0.53 |
| ▸ | NPC1 | O15118 | 8/20 | 0.48 |
| ▸ | RAB9A | P51151 | 6/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | CNR2 | P34972 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3269267 | 0.91 | PPARG (0.51) | PPARGPPARDPPARANPC1RAB9A | |
| SCHEMBL3270585 | 0.87 | NPC1 (0.50) | NPC1RAB9ASMN1; SMN2MAPT | |
| SCHEMBL1729140 | 0.85 | PPARG (0.60) | PPARGPPARDPPARANPC1RAB9A | |
| SCHEMBL239896 | 0.82 | HRH3 (0.46) | — | |
| SCHEMBL3268726 | 0.81 | HRH3 (0.45) | — | |
| SCHEMBL3265540 | 0.79 | MAPT (0.55) | NPC1RAB9ASMN1; SMN2MAPT | |
| SCHEMBL3265729 | 0.78 | NPC1 (0.52) | NPC1RAB9ASMN1; SMN2MAPT | |
| SCHEMBL334455 | 0.77 | NPC1 (0.62) | PPARGPPARDPPARANPC1RAB9A | |
| SCHEMBL3266256 | 0.76 | DEGS1 (0.48) | MAPT | |
| SCHEMBL335645 | 0.76 | NPC1 (0.64) | PPARGPPARDPPARANPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120004207-A1 | THERAPEUTIC USES OF DERIVATIVES OF PIPERIDINYL-AND PIPERIDINYL-ALKYL CARBAMATES | SANOFI-AVENTIS (FR) | 2012-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120004207-A1 | THERAPEUTIC USES OF DERIVATIVES OF PIPERIDINYL-AND PIPERIDINYL-ALKYL CARBAMATES | CLCN2, CLIC1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | PPARG 1053/4885PPARD 2333/4885PPARA 1093/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.